Disc Medicine (NASDAQ:IRON) Price Target Raised to $170.00

Posted by George Bondi on Oct 22nd, 2026

Disc Medicine (NASDAQ:IRON – Free Report) had its price target lifted by Cantor Fitzgerald from $125.00 to $170.00 in a research note released on Monday, MarketBeat reports. Cantor Fitzgerald currently has an overweight rating on the stock.

Several other equities research analysts have also recently commented on IRON. Jefferies Financial Group reiterated a “buy” rating and issued a $128.00 price target on shares of Disc Medicine in a research report on Thursday, September 10th. Wells Fargo & Company upped their price target on shares of Disc Medicine from $79.00 to $86.00 and gave the company an “overweight” rating in a report on Wednesday, September 16th. Wedbush restated an “outperform” rating and set a $100.00 price objective on shares of Disc Medicine in a research report on Thursday, September 10th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Disc Medicine in a research note on Thursday, September 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $90.00 price objective on shares of Disc Medicine in a research note on Monday, August 17th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Disc Medicine presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

Get Our Latest Stock Report on IRON

Disc Medicine Stock Down 4.4%

IRON opened at $76.00 on Monday. Disc Medicine has a one year low of $40.00 and a one year high of $99.50. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The stock’s fifty day moving average is $71.44 and its 200-day moving average is $71.47. The company has a market capitalization of $2.92 billion, a PE ratio of -11.55 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.17. On average, equities analysts predict that Disc Medicine will post -6.61 EPS for the current fiscal year.

Insider Activity

In related news, CEO John D. Quisel sold 33,000 shares of Disc Medicine stock in a transaction on Monday, August 17th. The stock was sold at an average price of $79.15, for a total value of $2,611,950.00. Following the transaction, the chief executive officer directly owned 226,064 shares in the company, valued at $17,892,965.60. The trade was a 12.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kevin Bitterman sold 25,519 shares of the business’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $80.23, for a total value of $2,047,389.37. Following the sale, the director directly owned 12,991 shares in the company, valued at $1,042,267.93. This trade represents a 66.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 173,046 shares of company stock worth $13,591,034. Insiders own 3.76% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

Hedge funds have recently modified their holdings of the stock. Pinnacle Associates Ltd. acquired a new position in shares of Disc Medicine in the 3rd quarter valued at $2,310,000. Assenagon Asset Management S.A. increased its stake in Disc Medicine by 191.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock worth $73,280,000 after purchasing an additional 735,300 shares in the last quarter. Opaleye Management Inc. increased its stake in Disc Medicine by 103.1% in the 2nd quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock worth $62,535,000 after purchasing an additional 434,000 shares in the last quarter. Engineers Gate Manager LP raised its holdings in Disc Medicine by 110.9% during the 2nd quarter. Engineers Gate Manager LP now owns 19,552 shares of the company’s stock worth $1,430,000 after buying an additional 10,282 shares during the period. Finally, Squarepoint Ops LLC raised its holdings in Disc Medicine by 139.3% during the 2nd quarter. Squarepoint Ops LLC now owns 75,872 shares of the company’s stock worth $5,549,000 after buying an additional 44,163 shares during the period. 83.70% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

Positive Sentiment: Analyst price targets increased: Jefferies raised its price target to $149, while Cantor Fitzgerald lifted its target to $170 following positive Phase 3 results for bitopertin. The upgrades reinforce optimism about the drug’s potential in erythropoietic protoporphyria and related conditions. Jefferies raises Disc Medicine price target Cantor Fitzgerald raises Disc Medicine price target
Positive Sentiment: $450 million financing strengthens the balance sheet: Disc Medicine priced an upsized offering of 6 million shares at $75 per share, with a possible 900,000-share overallotment. Proceeds will fund clinical development, research, and potential commercialization of bitopertin, potentially reducing financing risk and extending the company’s operating runway. Disc Medicine announces $450 million offering
Neutral Sentiment: Unusually high options activity indicates elevated trading interest and expectations for volatility, but the report does not establish a clear directional signal. Disc Medicine sees unusually high options volume
Negative Sentiment: Share dilution is weighing on the stock: The sale of 6 million new shares—following the previously announced $350 million offering—can reduce existing shareholders’ ownership percentage and create selling pressure around the $75 offering price.
Negative Sentiment: Director selling adds an overhang: Director Kevin Bitterman sold a combined 41,825 shares for approximately $3.35 million across October 19–21, materially reducing his direct holdings. The transactions were conducted under a pre-arranged Rule 10b5-1 plan, which makes them less informative about current management expectations but still represents potential supply. Disc Medicine insider transaction filing

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.